A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A02:01 complex

More effective treatments are needed for human papilloma virus (HPV)-induced cancers despite HPV virus vaccination. The oncogenic HPV protein targets are currently undruggable and intracellular and therefore there are no antibodies to these targets. Here we report the discovery of TCR mimic monoclon...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 17; no. 3; p. e0265534
Main Authors: Tao Dao, Sungsoo Mun, Tatyana Korontsvit, Abdul G Khan, Mary Ann Pohl, Thomas White, Martin G Klatt, David Andrew, Ivo C Lorenz, David A Scheinberg
Format: Journal Article
Language:English
Published: Public Library of Science (PLoS) 01-01-2022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:More effective treatments are needed for human papilloma virus (HPV)-induced cancers despite HPV virus vaccination. The oncogenic HPV protein targets are currently undruggable and intracellular and therefore there are no antibodies to these targets. Here we report the discovery of TCR mimic monoclonal antibodies (TCRm mAb) specific for the HPV E7 protein p11-19, YMLDLQPET, when presented on the cell surface in the context of HLA-A*02:01 by use of human phage display libraries. One of the mAbs, 3F8, was able to specifically mediate T cell- redirected cytotoxicity, in a bispecific T cell engager (BiTE) form. While further studies are required to assess the therapeutic potential of this approach, the study provided the proof of concept that TCRm mAb could be a therapeutic strategy for HPV-induced human cancers.
ISSN:1932-6203
DOI:10.1371/journal.pone.0265534